We aimed to investigate response and prognostic factors in patients with human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (mCRC) and compare the curative effects on patients who received different therapy regimens (including chemotherapy and chemotherapy combined with targeted drugs). |